Iruplinalkib in Patients with ALK-Positive CrizotinibResistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial

被引：0
|
作者：
Shi, Y. [1 ]
Chen, J. [2 ]
Zhang, H. [3 ]
Zhang, Z. [4 ]
Zhang, Y. [5 ,24 ]
Wang, Z. [6 ]
Zhang, S. [7 ]
Zhao, J. [8 ,16 ]
Liu, C. [9 ]
Wang, X. [10 ]
Zhao, Y. [11 ,12 ]
Hu, C. [4 ]
Yang, L. [13 ]
Hao, X. [1 ]
Wang, L. [1 ]
Liu, Y. [14 ]
Yu, Y. [15 ]
Zhao, J. [8 ,16 ]
Wang, M. [17 ]
Zhang, L. [18 ]
Sun, S. [19 ]
Hu, Y. [20 ]
Gu, K. [21 ]
Hang, X. [22 ]
Shan, J. [22 ,23 ]
Zhang, Y. [5 ,24 ]
Tan, B. [25 ]
Yang, W. [26 ]
Yang, R. [27 ]
Si, M. [28 ]
Li, H. [28 ]
Kang, X. [28 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Nat Canc Ctr, Natl Clin Res Ctr Cancer, Canc Hosp, Beijing, Peoples R China
[2] Hunan Tumor Hosp, Changsha, Peoples R China
[3] Air Force Med Univ, Affiliated Hosp 2, Xian, Peoples R China
[4] Anhui Prov Canc Hosp, Hefei, Peoples R China
[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[6] Shandong Prov Inst Canc Prevent & Treatment, Jinan, Peoples R China
[7] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
[8] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China
[9] Xingjiang Med Univ, Affiliated Tumour Hosp, Urumqi, Peoples R China
[10] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[11] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[12] Henan Canc Hosp, Zhengzhou, Peoples R China
[13] Gansu Prov Canc Hosp, Lanzhou, Peoples R China
[14] China Med Univ, Hosp 1, Shenyang, Peoples R China
[15] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[16] Peking Univ, Canc Hosp, Beijing, Peoples R China
[17] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China
[18] Yantai Yuhuangding Hosp, Yantai, Peoples R China
[19] Cent Hosp, Hubei Canc Hosp, Wuhan, Peoples R China
[20] Hubei Canc Hosp, Wuhan, Peoples R China
[21] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China
[22] Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China
[23] Army Med Ctr PLA, Chongqing, Peoples R China
[24] Nanjing Chest Hosp, Nanjing, Peoples R China
[25] North Sichuan Med Coll, Affiliated Hosp, Nanchong, Peoples R China
[26] Shanxi Prov Canc Hosp, Taiyuan, Peoples R China
[27] Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China
[28] Qilu Pharmaceut Co Ltd, Jinan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Iruplinalkib; Non-small cell lung cancer; Crizotinib-resistant;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.07
引用
收藏
页码：S203 / S203
页数：1
相关论文
共 50 条
  • [31] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [32] Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
    Zheng, Jing
    Wang, Tao
    Yang, Yunpeng
    Huang, Jie
    Feng, Jifeng
    Zhuang, Wu
    Chen, Jianhua
    Zhao, Jun
    Zhong, Wei
    Zhao, Yanqiu
    Zhang, Yiping
    Song, Yong
    Hu, Yi
    Yu, Zhuang
    Gong, Youling
    Chen, Yuan
    Ye, Feng
    Zhang, Shucai
    Cao, Lejie
    Fan, Yun
    Wu, Gang
    Guo, Yubiao
    Zhou, Chengzhi
    Ma, Kewei
    Fang, Jian
    Feng, Weineng
    Liu, Yunpeng
    Zheng, Zhendong
    Li, Gaofeng
    Wang, Huijie
    Cang, Shundong
    Wu, Ning
    Song, Wei
    Liu, Xiaoqing
    Zhao, Shijun
    Ding, Lieming
    Selvaggi, Giovanni
    Wang, Yang
    Xiao, Shanshan
    Wang, Qian
    Shen, Zhilin
    Zhou, Jianya
    Zhou, Jianying
    Zhang, Li
    CANCER COMMUNICATIONS, 2024, 44 (04) : 455 - 468
  • [33] Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
    Camidge, D. Ross
    Dziadziuszko, Rafal
    Peters, Solange
    Mok, Tony
    Noe, Johannes
    Nowicka, Malgorzata
    Gadgeel, Shirish M.
    Cheema, Parneet
    Pavlakis, Nick
    de Marinis, Filippo
    Cho, Byoung Chul
    Zhang, Li
    Moro-Sibilot, Denis
    Liu, Ting
    Bordogna, Walter
    Balas, Bogdana
    Mueller, Barbara
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : 1233 - 1243
  • [34] A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Kim, D. W.
    Blackhall, F.
    Soria, J. C.
    Solomon, B.
    Camidge, D. R.
    Riely, G. J.
    Bottomley, A.
    Tassell, V.
    Polli, A.
    Shaw, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S617 - S617
  • [35] Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
    Gettinger, S. N.
    Bazhenova, L. A.
    Salgia, R.
    Langer, C. J.
    Gold, K.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Dorer, D. J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, D. R.
    LUNG CANCER, 2016, 91 : S20 - S21
  • [36] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice
    Weiss, Glen J.
    Dorer, David J.
    Rivera, Victor M.
    Conlan, Maureen G.
    Kerstein, David
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239
  • [37] Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid)
    Nakatani, Y.
    Nosaki, K.
    Sugimoto, A.
    Udagawa, H.
    Kato, T.
    Sakakibara-Konishi, J.
    Horinouchi, H.
    Ohashi, K.
    Toyozawa, R.
    Sakamoto, T.
    Morise, M.
    Ikeno, T.
    Nomura, S.
    Izumi, H.
    Matsumoto, S.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S352 - S352
  • [38] Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC
    Soo, R.
    Lin, C.
    Kim, D.
    Seto, T.
    Tan, E.
    Hayashi, H.
    Abbattista, A.
    Martini, J.
    Wong, C. H.
    Toffalorio, F.
    Solomon, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S660 - S660
  • [39] Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LW: Results from the phase II, ASCEND-7 study
    Barlesi, F.
    Kim, D. -W.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Garrido Lopez, P.
    Orlov, S.
    Majem, M.
    McKeage, M.
    Yu, C. -J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Chow, L. Q.
    ANNALS OF ONCOLOGY, 2019, 30 : 143 - +
  • [40] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
    Nishio, Makoto
    Yoshida, Tatsuya
    Kumagai, Toru
    Hida, Toyoaki
    Toyozawa, Ryo
    Shimokawaji, Tadasuke
    Goto, Koichi
    Nakagawa, Kazuhiko
    Ohe, Yuichiro
    Seto, Takashi
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
12345